Multiple myeloma is a neoplastic disorder of plasma cells. Plasma cell neoplasms can present as a single lesion (solitary plasmacytoma) or as multiple lesions (multiple myeloma). Solitary plasmacytomas can occur in bone (plasmacytoma of bone), or in soft tissues (extramedullary plasmacytoma). The bone lesions are due to monoclonal or malignant plasma cell infiltration. After relapse the patient most commonly presents with medullary disease but occasionally can have extramedullary involvement.
Introduction
Multiple myeloma is a neoplastic disorder of plasma cells. Plasma cell neoplasms can present as a single lesion (solitary plasmacytoma) or as multiple lesions (multiple myeloma) [1] . Solitary plasmacytomas can occur in bone (plasmacytoma of bone), or in soft tissues (extramedullary plasmacytoma). The bone lesions are due to monoclonal or malignant plasma cell infiltration. After relapse the patient most commonly presents with medullary disease but occasionally can have extramedullary involvement. We present here a case of multiple myeloma who at the time of relapse developed large plasmacytoma of the skull.
Case presentation
A 68 years old female patient was diagnosed as a case of multiple myeloma 4 years back. She had received 4 cycles of Bortezomib/ Thalidomide/dexamethasone chemotherapy and had refused for autologous stem cell transplant. She presented with progressively increasing mass over the skull (Figure 1 ), further evaluation revealed relapse of multiple myeloma with serum protein electrophoresis showing M band of 3.2g/dl. Her hemoglobin was 8.1g/dl. Her liver and kidney function profile were normal. She was treated with lenalidomide and dexamethasone therapy but did not have any clinically significant decrease in skull mass on follow-up. This case highlights the extramedullary manifestations of relapsed multiple myeloma.
Discussion
Myeloma is the most common plasma cell neoplasm. It presents clinically with serum monoclonal immunoglobulins (M protein), lytic bone lesions, anemia, renal impairment, and hypercalcemia [1, 2] .
Extramedullary plasmacytomas can arise anywhere in the body. Definitive diagnosis requires fine needle aspiration or biopsy of the mass lesion. In a study, 7% of patients developed extramedullary involvement at the time of diagnosis and 6% of patients developed soft-tissue extramedullary plasmacytomas at 30-month follow-up [3] . Head and neck is the commonest site of plasma cell involvement [4] . Patients with extramedullary relapse have significantly shorter overall survival than patients without extramedullary relapse [5] . Radiotherapy is the treatment of choice for patients with solitary plasmacytoma but patients with associated myeloma with require systemic treatment as well. 
